BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its ...
BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ...
BridgeBio Pharma recently reported multiple developments, including new post-hoc analyses in Circulation: Heart Failure ...
ATTR-CM treatment options narrowed after AstraZeneca and Ionis revealed their gene-silencing drug Wainua (eplontersen) failed ...
AstraZeneca and Ionis missed a key heart-drug trial goal, shifting attention to BridgeBio’s approved ATTR-CM treatment.
BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential ...
Shares in AstraZeneca were trading down more than 8% this morning after it revealed that its transthyretin amyloidosis (ATTR) ...
Zacks Investment Research on MSN
Can Alnylam's drug pipeline fuel its long-term revenue growth?
Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo and Amvuttra — that together ...
The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent ...
AstraZeneca and Ionis both saw their stocks take a hit on 9 July following the ATTR-CM trial failure.
Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.
BridgeBio’s Attruby preserves kidney function in patients with transthyretin amyloidosis cardiomyopathy, an effect that is “distinct” from other drugs in this space, according to Jefferies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results